Found: 9
Select item for more details and to access through your institution.
Terapia biológica en cáncer: nuevos tiempos con una visión optimista.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
Das Spliceosom als Angriffspunkt für Pharmaka.
- Published in:
- Angewandte Chemie, 2017, v. 129, n. 40, p. 12218, doi. 10.1002/ange.201701065
- By:
- Publication type:
- Article
A Challenging Pie to Splice: Drugging the Spliceosome.
- Published in:
- Angewandte Chemie International Edition, 2017, v. 56, n. 40, p. 12052, doi. 10.1002/anie.201701065
- By:
- Publication type:
- Article
Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective.
- Published in:
- Current Oncology Reports, 2022, v. 24, n. 12, p. 1863, doi. 10.1007/s11912-022-01330-z
- By:
- Publication type:
- Article
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1200914
- By:
- Publication type:
- Article
It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy.
- Published in:
- Hematology Reports, 2023, v. 15, n. 1, p. 1, doi. 10.3390/hematolrep15010001
- By:
- Publication type:
- Article
Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage–colony-stimulating factor and granulocyte–colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation
- Published in:
- Transfusion, 2007, v. 47, n. 11, p. 2153, doi. 10.1111/j.1537-2995.2007.01440.x
- By:
- Publication type:
- Article
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0435-x
- By:
- Publication type:
- Article
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
- Published in:
- Advances in Hematology, 2022, p. 1, doi. 10.1155/2022/4450824
- By:
- Publication type:
- Article